1. Analyst View
2. Research Methodology
3. Liquid Biopsy - An Introduction
4. Market Dynamics
4.1 Market Drivers
4.1.1 High Prevalence of Cancer
4.1.2 Technological Advancements in Personalized Therapies
4.1.3 Increasing Demand for Minimally-Invasive Biopsy Techniques
4.1.4 Lower Cost
4.1.5 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 A Less-Defined Regulatory Environment
4.2.2 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
4.2.3 Need for Proper Handling and Storage of the Samples
4.3 Market Opportunities
4.3.1 Exosomes Offer Great Advantages as Source Materials
4.3.2 Next Generation Sequencing Offers Significant Opportunity
4.3.3 Prenatal Screening & Organ Transplantation: Upcoming Applications
4.3.4 Growing Researches on Cerebrospinal Fluid as Sample Source
4.4 Industry Trends
4.4.1 Strong Preference for ctDNA Among Various Biomarkers
4.4.2 Blood: The Most Widely Used Sample
5. Global Liquid Biopsy Market Outlook to 2020
6. Global Liquid Biopsy Market Size by Technology
6.1 Circulating Tumor Cells (CTCs)
6.2 Circulating Tumor DNA/Cell free DNA (ctDNA/cfDNA)
6.3 Exosomes
7. Global Liquid Biopsy Market Size by Sample Type
7.1 Blood
7.2 Urine
8. Global Liquid Biopsy Market Size by Geography
8.1 North America
8.2 Europe
8.3 Asia
8.4 Rest of the World (RoW)
9. Pipeline Analysis
10. Key Player Analysis
10.1 Personal Genome Diagnostics
10.2 Guardant Health, Inc.
10.3 Pathway Genomics
10.4 NeoGenomics, Inc.
10.5 RainDance Technology
10.6 Trovagene, Inc.
10.7 Circulogene Theranostics
10.8 Biocartis
10.9 Cynvenio Biosystems, Inc.
10.10 Biocept, Inc.
10.11 ANGLE plc
10.12 MDxHealth
10.13 Clearbridge BioMedics Pte Ltd
10.14 Exosome Diagnostics, Inc.